v3.26.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 1 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
$ / shares
shares
Mar. 25, 2025
USD ($)
Sep. 30, 2025
USD ($)
Mar. 31, 2026
USD ($)
Segment
$ / shares
shares
Mar. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
Aug. 05, 2024
$ / shares
shares
Mar. 31, 2024
USD ($)
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Cash and cash equivalents $ 5,024,000     $ 5,024,000 $ 11,312,000      
Restricted cash 143,000     143,000 143,000      
Accumulated deficit (356,000,000)     (356,000,000) (342,157,000)      
Cash flow from operations       10,827,000 9,461,000      
Total current assets 6,627,000     6,627,000 12,131,000      
Total current liabilities 2,785,000     2,785,000 $ 3,737,000      
Working capital $ 3,800,000     $ 3,800,000        
Issuance of common stock | shares 2,894,519     2,894,519 1,898,068      
Net proceeds from issuance of offerings       $ 1,800,000        
Net proceeds       4,808,000 $ 8,847,000      
Loss on issuance of common stock       2,703,000 0      
Stockholders' equity $ (1,099,000)     (1,099,000) 10,492,000      
Proceeds from issuance of common stock, net       $ 4,808,000 8,847,000      
Insurance premium financing agreement description       In September 2025, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 7.82%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $40,468 over the term of the agreement, which will mature in June 2026. The insurance premium financing liability was approximately $0.1 million as of March 31, 2026 and 2025, respectively.        
Financing agreement amount     $ 400,000          
Percentage of down payment     10.00%          
Insurance premium financing liability 118,000     $ 118,000 128,000      
Prepaid insurance 280,000     280,000 417,000      
Restricted cash 100,000     $ 100,000 100,000      
Estimated useful life of the fixed assets       The estimated useful lives of the fixed assets range between one and seven years        
Impairment of long-lived assets       $ 0 0      
Escrow receivable 0     0 1,000,000      
Period of escrow   15 months            
Dilutive effect       $ 0 $ 0      
Common stock equivalents excluded from computing diluted net loss per share | shares       5,000,000 700,000      
Operating segment | Segment       1        
Insurance Premium Financing Liability [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Annual interest rate     7.82%          
Monthly principal and interest payments     $ 40,468          
Prepaid insurance $ 200,000     $ 200,000 $ 200,000      
Common Warrants [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Issuance of warrants | shares 429,836     429,836     130,202  
Stock offering price per share | $ / shares $ 1.14     $ 1.14     $ 9.6  
Warrants exercise price per share | $ / shares 1.71     1.71        
Placement Agent Warrants [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Warrants exercise price per share | $ / shares $ 1.43     $ 1.43 $ 0      
Fair value of the warrants $ 100,000     $ 100,000        
Common stock warrant liability $ 100,000     $ 100,000        
Maximum [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Useful life of fixed assets, range 7 years     7 years        
Minimum [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Percentage of Drug Candidate       10.00%        
Useful life of fixed assets, range 1 year     1 year        
At The Market Facility [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Issuance of common stock | shares 701,729     701,729        
Issuance of common stock | shares       701,729        
2026 Offering [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Issuance of common stock | shares 286,557              
Accompanying warrants issued | shares 429,836              
Gross proceeds $ 3,000,000              
Net proceeds 2,400,000              
Fair value of the warrants 5,700,000     $ 5,700,000        
Loss on issuance of common stock       2,700,000        
Common stock warrant liability 5,700,000     $ 5,700,000        
Proceeds from issuance of common stock, net $ 2,400,000              
2026 Offering [Member] | Common Warrants [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Accompanying warrants issued | shares 3,517,533              
Issuance of warrants | shares 429,836     429,836        
Stock offering price per share | $ / shares $ 1.14     $ 1.14        
Warrants exercise price per share | $ / shares $ 1.71     1.71        
2026 Offering [Member] | Pre-Funded Warrants [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Issuance of common stock | shares 2,345,022              
Stock offering price per share | $ / shares $ 1.139     $ 1.139        
2026 Offering [Member] | Placement Agent Warrants [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Issuance of common stock | shares 131,579              
Issuance of warrants | shares 131,579     131,579        
Warrants exercise price per share | $ / shares $ 1.425     $ 1.425        
2026 Offering [Member] | Maximum [Member] | Common Warrants [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Issuance of common stock | shares 3,517,533              
Metacrine's FXR Program [Member] | Maximum [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Future milestone         $ 50,000,000      
Potential milestone payments       $ 50,000,000        
Metacrine's FXR Program [Member] | Metacrine, Inc. [Member]                
Description Of Business And Summary Of Significant Accounting Policies [Line Items]                
Consideration of cash payments           $ 4,000,000    
Upfront payment   $ 10,000,000       $ 2,000,000    
Closing upfront payment   9,000,000            
Acquired in-process research and development               $ 2,000,000
Escrow receivable   $ 1,000,000